Federal Circuit Rejects Claim Construction That Contradicts Dependent Claims
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
BAXALTA INC. V. GENENTECH, INC.
Before Moore, Plager, and Wallach. Appeal from the District of Delaware
Summary: A district court erred by interpreting a specification’s description of an “antibody” as a definition, when that description contradicted other portions of the specification and several dependent claims.
At the district court, Baxalta and Genetech disputed the construction of “antibody.” The court determined that the specification had expressly defined “antibody” consistent with the narrow construction Genentech proposed. Although the court recognized that this construction was inconsistent with several dependent claims, it ruled that the express definition controlled, rendering the dependent claims invalid. The parties stipulated to non-infringement under the district court’s narrow construction, and Baxalta appealed.
The Federal Circuit ruled that the plain language of the independent claim did not require any particular definition of “antibody,” and that the dependent claims confirmed that the independent claim used a broad meaning of “antibody.” The district court’s construction, which excluded the embodiments in the dependent claims, was “inconsistent with the plain language of the claims.” The Federal Circuit rejected the district court’s conclusion that the specification expressly defined “antibody.” Although the passage the district court relied on was plausibly definitional in isolation, a definitional reading of the passage rendered the specification as a whole internally inconsistent. The Federal Circuit therefore determined that the passage was a “generalized introduction,” not a definition. Accordingly, the Federal Circuit broadened the construction of “antibody,” vacated the judgment of non-infringement, and remanded for further proceedings.
Editor: Paul Stewart
Written by: Brandon G. Smith & Jeremy Anapol
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…